Key Highlights

  • Q1 Revenue of $12.49 million rose 32% year-over-year, exceeding analyst estimates.
  • Adjusted EBITDA loss narrowed significantly to $326,000, demonstrating Operating Leverage.
  • Surgical Aesthetics segment and international sales were primary growth drivers.
  • Full-year 2026 revenue guidance raised to $59–$60 million, signalling management confidence.
  • Shares closed up 22% at $3.56, the strongest single-day gain in recent quarters.

 

Apyx Medical delivered a first-quarter performance that combined revenue outperformance, Margin improvement, and guidance upgrade — the trifecta most likely to drive a meaningful re-rating in a small-cap medical technology company. Shares closed up 22% at $3.56, a move that reflects the market's positive reassessment of a Business that has been quietly rebuilding its commercial trajectory.

First-quarter revenue of $12.49 million represents 32% growth year-over-year, a pace that comfortably exceeded consensus estimates and validates the company's strategy of concentrating commercial resources on its highest-margin, highest-growth segments. The Surgical Aesthetics division — centred on Apyx's proprietary J-Plasma technology, which delivers cold plasma energy for soft tissue coagulation and ablation — has emerged as the primary growth engine.

International sales have also been a meaningful contributor, a dynamic that speaks to the broadening geographic footprint of J-Plasma adoption. Medical aesthetics is a category with strong structural growth tailwinds across markets, driven by demographic Demand, increasing patient awareness, and the ongoing professionalisation of the specialty. Apyx's technology, positioned at the intersection of energy-based aesthetics and minimally invasive surgery, benefits from both trends.

Perhaps most notable was the adjusted EBITDA loss of just $326,000 — a figure that, while still negative, represents a dramatic narrowing relative to prior quarters and suggests that the company is approaching the inflection point at which revenue scale begins to generate meaningful operating leverage. For a business of Apyx's size, crossing into consistent EBITDA positivity would represent a significant de-risking event.

The raised full-year guidance of $59–$60 million implies continued double-digit growth over the remaining three quarters, a projection that management clearly believes is grounded in visible pipeline and order book strength.

If the company executes to the midpoint of that range, the 22% single-day gain may look modest in retrospect. The broader question is whether the Surgical Aesthetics category can sustain its momentum as physician awareness of J-Plasma matures into a larger, more competitive market. For now, the evidence points firmly in Apyx's favour.

APYX (Nasdaq) closed at $3.56, +22% on May 8, 2026. This article is for informational purposes only and does not constitute Investment advice.